Dept Health (UK).Report on Health and Social Subjects No 35. Guidelines for the Testing of Chemicals for MutagenicityHMSO (1989 ).
2.
EEC Council Directive 92/32/EEC of 30 April 1992 amending for the 7th time Directive 67/548/EEC on the approximation of the laws, regulations and administration provisions relating to the classification, packaging and labelling of dangerous substances. 1992 Official J. No. L154/15 June 1992. 65-80.
3.
Ashby J., Waters MD, Preston J. et al. IPCS harmonisation of methods for the prediction and quantification of human carcinogenic/mutagenic hazard and for indicating the probable mechanism of action of carcinogens. Mut. Res., 1996 ; 342: 153-157.
4.
Shih C., Padhy LC, Murray W., Weinberg RATransforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature1981; 290: 261-264.
5.
Krontiris TG , Cooper GMTransforming activity of human tumour DNAs . Proc Nat Acad Sci USA1981; 78: 1181-1184.
6.
Tabin CJ, Bradley SM, Bargmann CI et al. Mechanism of activation of a human oncogene. Nature1982; 300: 143 -149.
7.
Taparowsky E. , Suard Y., Fasano O. et al. Activation of T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature1982; 300: 712 -715.
8.
Fearon E. and Volgelstein B.A genetic model for colorectal tumorigenesis. Cell1990; 61: 759-67.
9.
Purchase Ifh.Current knowledge of mechanisms of carcinogenicity: genotoxins versus non-genotoxins. Human and Experimental Toxicology1994; 13: 17-28.
10.
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Testing for carcinogenicity of pharmaceuticals. Step 2 consensus draft May 1996.
